Prometic announces second annual plasminogen deficiency awareness week

October 26, 2018 Frederic Dumais

LAVAL, QUEBEC, CANADA, – October 25, 2018 – Prometic Life Sciences Inc. (TSX:
PLI) (OTCQX: PFSCF) (“Prometic” or the “Corporation”) is pleased to invite you to its
second annual Plasminogen Deficiency Awareness Week, from November 5 to 8, 2018.


This initiative, sponsored by Prometic, aims to raise awareness and improve understanding of this rare disease and its effects. Plasminogen Deficiency Awareness Week is a free 4-day online event available at plgdweek.com. where participants will have access to:


• Educational webinars and videos
• Case studies
• Answers to common questions and concerns patients and caregivers may have at
various times through their journey
• Testimonials from patients
• And more!


To address the needs and interests of a broad stakeholder audience, there will be activities and content dedicated specifically to patients & caregivers, while other material and information may be of particular interest to healthcare providers.


Prometic is dedicated to making a difference by developing a plasminogen replacement therapy, for congenital plasminogen deficiency, which is currently under review by the FDA. “At Prometic, we are passionate about developing solutions for unmet medical needs for rare diseases. We are committed to developing drugs that help address challenging, orphan medical conditions”, says Pierre Laurin, President and CEO, Prometic Life Sciences Inc.


Plasminogen Deficiency Awareness Week revolves around sharing knowledge and testimonials. The idea is to build a community of people affected directly or indirectly by this disease – because sharing is a part of healing! Subscribe at plgdweek.com


About Plasminogen Deficiency The most common condition associated with plasminogen deficiency is ligneous conjunctivitis, which is characterized by thick, woody (ligneous) growths on the
conjunctiva of the eye, and if left untreated, can lead to corneal damage and blindness. Ligneous growths tend to recur after surgical excision, thereby requiring multiple surgeries.


While ligneous conjunctivitis is the best characterized lesion of plasminogen deficiency, hypoplasminogenemia is a multi-systemic disease that can also affect the ears, sinuses,
tracheobronchial tree, genitourinary tract, and gingiva. Tracheobronchial lesions including hyper viscous secretions can result in respiratory failure. Hydrocephalus has also been reported in children with severe hypoplasminogenemia, apparently related to the deposition of fibrin in the cerebral ventricular system.

About Prometic Life Sciences Inc.

Prometic (www.prometic.com) is a publicly traded (TSX symbol: PLI) (OTCQX symbol:
PFSCF) biopharmaceutical corporation with two drug discovery platforms focusing on
unmet medical needs. The first platform (small molecule therapeutics) stems from the
discovery of two receptors which we believe are at the core of how the body heals:
namely, promoting tissue regeneration and scar resolution as opposed to fibrosis. One of
the lead drug candidates emerging from this platform, PBI-4050, is expected to enter
pivotal phase 3 clinical trials for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The second drug discovery and development platform (plasma-derived therapeutics)
leverages Prometic’s experience in bioseparation technologies used to isolate and purify
biopharmaceuticals from human plasma. The Corporation’s primary goal with respect to
this second platform is to address unmet medical needs with therapeutic proteins not
currently commercially available, such as Ryplazim™ (plasminogen). We are also
leveraging this platform’s higher recovery yield potential to advance established plasmaderived
therapeutics such as Intravenous Immunoglobulin (IVIG). The Corporation also
provides access to its proprietary bioseparation technologies to enable pharmaceutical
companies in their production of non-competing biopharmaceuticals. Recognized as a
bioseparations expert, the Corporation derives revenue from this activity through sales of
affinity chromatography media which contributes to offset the costs of its own R&D
investments.


We are headquartered in Laval, Quebec (Canada) and have R&D facilities in Canada,
the United Kingdom (“UK”) and the United States (“USA”), manufacturing facilities in
Canada and the Isle of Man and corporate and business development activities in
Canada, the USA, and Europe.


Forward Looking Statements
This press release contains forward-looking statements about Prometic’s objectives,
strategies and businesses that involve risks and uncertainties. These statements are
“forward-looking” because they are based on our current expectations about the markets
we operate in and on various estimates and assumptions. Actual events or results may
differ materially from those anticipated in these forward-looking statements if known or
unknown risks affect our business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited to, Prometic’s ability
to develop, manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Prometic to take advantage of
business opportunities in the pharmaceutical industry, uncertainties related to the
regulatory process and general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or results to materially
differ from our current expectations in Prometic’s Annual Information Form for the year
ended December 31, 2017 under the heading “Risk and Uncertainties related to
Prometic’s business”. As a result, we cannot guarantee that any forward-looking
statement will materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of future events or for
any other reason, unless required by applicable securities laws and regulations. All
amounts are in Canadian dollars unless indicated otherwise.

For further information please contact:


Corporate Contacts:
Pierre Laurin
President and CEO
Prometic Life Sciences Inc.
p.laurin@prometic.com
450.781.0115


Frederic Dumais
Senior Director, Communications & Investor Relations
Prometic Life Sciences Inc.
f.dumais@prometic.com
450-781-0115

Previous Article
Prometic announces extension of debt maturities to 2024
Prometic announces extension of debt maturities to 2024

Next Flipbook
Annual Information Form 2017
Annual Information Form 2017

Prometic Annual Information Form 2017